Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.52 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.51 |
| ▸ | ABAT | P80404 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988294 | 0.88 | ABCB1 (0.47) | MAPK1ALDH1A1SMN1; SMN2HPGDTP53 | |
| Trifluoromethanesulfonic Acid SCHEMBL7493539 | 0.87 | CA12 (0.48) | MAPK1ALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL9722263 | 0.86 | MAPT (0.51) | MAPK1ALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL1852678 | 0.85 | GPR35 (0.56) | MAPK1ALDH1A1SMN1; SMN2HPGDGPR35 | |
| SCHEMBL1581489 | 0.85 | GPR35 (0.60) | MAPK1ALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL8225900 | 0.83 | ERN1 (0.50) | MAPK1ALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL1662886 | 0.82 | ALDH1A1 (0.65) | MAPK1ALDH1A1SMN1; SMN2TSHRMAPT | |
| SCHEMBL7010553 | 0.82 | ALDH1A1 (0.49) | MAPK1ALDH1A1SMN1; SMN2HPGDTP53 | |
| SCHEMBL11258868 | 0.81 | ALDH1A1 (0.55) | MAPK1ALDH1A1SMN1; SMN2HPGDMAPT | |
| SCHEMBL10340370 | 0.81 | ALDH1A1 (0.61) | MAPK1ALDH1A1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684169-A | Synthesis method of Iguratimod intermediate impurity and application of impurity | 常州佳德医药科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-7067024-B2 | Reduced sensitivity, melt-pourable TNT replacements | ALLIANT TECHSYSTEMS INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | claimed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | claimed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | claimed |
| EP-1399400-A1 | REDUCED SENSITIVITY, MELT-POURABLE TNT REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2004-03-24 | — | — | EP | claimed |
| EP-1399399-A1 | REDUCED SENSITIVITY, MELT-POURABLE TRITONAL REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2004-03-24 | — | — | EP | claimed |
| US-6648998-B2 | Mixture; replacement of trinitrotoluene with (mono or di)nitro aromatic compounds | ALLIANT TECHSYSTEMS INC. | 2003-11-18 | — | — | US | claimed |
| US-20030140993-A1 | Reduced sensitivity, melt-pourable tritonal replacements | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003002486-A1 | REDUCED SENSITIVITY, MELT-POURABLE TNT REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2003-01-09 | — | — | WO | claimed |
| WO-2003002485-A1 | REDUCED SENSITIVITY, MELT-POURABLE TRITONAL REPLACEMENTS | ALLIANT TECHSYSTEMS INC. (US) | 2003-01-09 | — | — | WO | claimed |
| US-20030005988-A1 | Reduced sensitivity, melt-pourable TNT replacements | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2003-01-09 | — | — | US | claimed |
| US-20020038682-A1 | Reduced sensitivity melt-cast explosives | Northrop Grumman Innovation Systems, Inc. | 2002-04-04 | — | — | US | claimed |
| WO-2001046091-A1 | REDUCED SENSITIVITY MELT-CAST EXPLOSIVES | DOLL, DANIEL, W. | 2001-06-28 | — | — | WO | claimed |
| JP-59128394-A | — | — | None | — | — | JP | disclosed |
| US-3947434-A | 9-(P-phenylazoanilino)-7-methyl-1H-imidazo[4,5-f]quinolines | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | MAPK1 2044/4885ALDH1A1 2021/4885SMN1; SMN2 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.